Natco Pharma's Hyderabad Facility Receives VAI Classification from FDA

Natco Pharma Ltd's Pharma Division in Kothur, Hyderabad, India has received an Establishment Inspection Report (EIR) from the U.S. Food and Drug Administration (FDA), classifying the facility as 'Voluntary Action Indicated (VAI)'. This comes after the FDA conducted an inspection at the facility. The VAI classification indicates that the inspection findings did not require regulatory action, but the firm voluntarily acted to correct the objectionable conditions. This is a significant update for Natco Pharma and its stakeholders.